Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial

Arthur A. Vandenbark, Yuan K. Chou, Ruth Whitham, Michele Mass, Abigail Buenafe, Diane Liefeld, Daniel Kavanagh, Shelley Cooper, George A. Hashim, Halina Offner, Dennis N. Bourdette

Research output: Contribution to journalArticlepeer-review

179 Scopus citations

Abstract

A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)1109-1115
Number of pages7
JournalNature medicine
Volume2
Issue number10
DOIs
StatePublished - Oct 1996

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial'. Together they form a unique fingerprint.

Cite this